Purinogenic Immunodeficiency Diseases

DIFFERENTIAL EFFECTS OF DEOXYADENOSINE AND DEOXYGUANOSINE ON DNA SYNTHESIS IN HUMAN T LYMPHOBLASTS

JAMES M. WILSON, BEVERLY S. MITCHELL, PETER E. DADDONA, and WILIAM N. KELLEY, Departments of Internal Medicine and Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan 48109

ABSTRACT Deoxadenosine and deoxyguanosine are toxic to human lymphoid cells in culture and have been implicated in the pathogenesis of the immunodeficiency states associated with adenosine deaminase and purine nucleoside phosphorylase deficiency, respectively. We have studied the relative incorporation of several labeled nucleosides into DNA and into nucleotide pools to further elucidate the mechanism of deoxyribonucleoside toxicity. In the presence of an inhibitor of adenosine deaminase (erythro-9-(2-hydroxy-3-nonyl)adenine; EHNA), deoxadenosine (1–50 μM) progressively decreased the incorporation of thymidine, uridine, and deoxyuridine into DNA, but did not affect uridine incorporation into RNA. This decrease in DNA synthesis was associated with increasing dATP and decreasing dCTP pools. Likewise, incubation of cells with deoxyguanosine caused an elevation of dGTP, depletion of dCTP, and inhibition of DNA synthesis.

To test the hypothesis that dATP and dGTP accumulation inhibit DNA synthesis by inhibiting the enzyme ribonucleotide reductase, simultaneous rates of incorporation of [3H]uridine and [14C]thymidine into DNA were measured in the presence of deoxadenosine plus EHNA or deoxyguanosine, and in the presence of hydroxyurea, a known inhibitor of ribonucleotide reductase. Hydroxyurea (100 μM) and deoxyguanosine (10 μM) decreased the incorporation of [3H]uridine but not of [14C]thymidine into DNA; both compounds also substantially increased [14C]adenosine incorporation into the ribonucleotide pool while reducing incorporation into the deoxyribonucleotide pool. In contrast, deoxadenosine plus EHNA did not show this differential inhibition of [3H]uridine incorporation into DNA, and the alteration in [3H]cytidine incorporation into nucleotide pools was less impressive.

These data show an association between accumulation of dATP or dGTP and a primary inhibition of DNA synthesis, and they provide support for ribonucleotide reductase inhibition as the mechanism responsible for deoxyguanosine toxicity. Deoxadenosine toxicity, however, appears to result from another, or perhaps a combination of, molecular event(s).

INTRODUCTION

The association of at least two inborn errors of purine metabolism with immunodeficiency diseases has made possible the investigation of these diseases at the molecular level. Adenosine deaminase (ADA) deficiency results in severe combined immunodeficiency disease with impairment of T- and B-lymphocyte function (1). Purine nucleoside phosphorylase (PNP) deficiency has been associated with T-lymphocyte dysfunction in nine patients (2–9). The mechanism(s) whereby these enzyme deficiency states affect lymphocyte development and/or function has not been fully elucidated. However, the recent findings of markedly elevated dATP levels in ADA-deficient erythrocytes (10, 11) and of dGTP levels in PNP-deficient erythrocytes (12) in conjunction with high-circulating or urinary levels of the corresponding deoxyribonucleotide in these patients (3, 13) provide support for the hypothesis that deoxyribonucleosides play an important role in the

1 Abbreviations used in this paper: ADA, adenosine deaminase; EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine; PCA, perchloric acid; PNP, purine nucleoside phosphorylase.
pathogenesis of the immune dysfunction in these two diseases and suggest that deoxyribonucleosides or their metabolites may be toxic to lymphoid cells.

The purine deoxyribonucleosides have indeed been shown to have lymphocytotoxic effects in vitro. Deoxyadenosine in the presence of an inhibitor of ADA inhibits [3H]thymidine incorporation into DNA by peripheral blood lymphocytes (14) and is toxic in micromolar concentrations to a variety of mouse (15, 16) and human (17, 18) lymphoid cell lines. Deoxyguanosine in the absence of a PNP inhibitor is likewise extremely toxic to lymphoid cells in culture (18-20). In addition, the rather striking selectivity of both deoxyadenosine and deoxyguanosine toxicity for human lymphoblasts of T-cell origin, as opposed to B-cell origin (18, 21), has provided a potential explanation for the prominent T-cell dysfunction in patients with ADA and PNP deficiency, respectively.

The cytotoxic effects of deoxyadenosine and deoxyguanosine on cultured cells correlate well with an accumulation of the corresponding deoxyribonucleoside triphosphate and are also associated with a decrease in the intracellular dCTP pool (15, 16, 19, 20). These observations, in conjunction with substantial reversal of toxicity in several culture systems with exogenous deoxycytidine (16-20), have led many investigators to suggest inhibition of the enzyme ribonucleotide reductase by dATP or dGTP as the mechanism underlying cellular toxicity (10, 16, 17, 20). Ribonucleotide reductase is responsible for catalyzing the reduction of all ribonucleoside diphosphates, and, thus, this enzyme appears to be important in the control of DNA synthesis. It is subject to strong negative allosteric control by deoxyribonucleoside triphosphates (22). Theoretically, therefore, accumulation of dATP or dGTP could inhibit ribonucleotide reductase, thus inhibiting the conversion of CDP to dCDP and dCTP. dCTP has been postulated to play a major regulatory role in the control of DNA synthesis in Chinese hamster ovary cells, and a decrease in the dCTP pool correlates well with inhibition of DNA synthesis in these cells (23). Direct phosphorylation of exogenous deoxycytidine could bypass the requirement for ribonucleotide reductase, replenish the dCTP pool, and restore DNA synthesis. Despite the logic of this thesis, there is no direct evidence for inhibition of ribonucleotide reductase in intact human lymphoid cells under conditions that cause cellular toxicity, although such evidence does exist for deoxyguanosine-mediated toxicity in a mouse T-lymphoma line (24).

We have studied the effects of deoxyadenosine and deoxyguanosine on DNA synthesis in human T lymphoblasts to investigate more directly the molecular mechanism of deoxyribonucleoside toxicity in these cells. In addition, we have used the differential incorporation of several labeled ribonucleosides and deoxyribonucleosides into DNA, into RNA, and into ribonucleotide pools to assess the effects of deoxyadenosine and deoxyguanosine on ribonucleotide reductase activity. Whereas our results provide more direct evidence for the inhibition of ribonucleotide reductase in deoxyguanosine toxicity, they also suggest that additional factors may play a role in the toxicity of deoxyadenosine.

**METHODS**

*Radioisotopes and chemicals.* [3H]Cytidine (28.0 Ci/mmol), [3H]thymidine (4.2 Ci/mmol), [3H]deoxyguanosine (21.9 Ci/mmol), [3H]dTTP (18.3 Ci/mmol), and [3H]dCTP (22.3 Ci/mmol) were obtained from New England Nuclear (Boston, Mass.), and [U-14C]thymidine (515 mCi/mmol) and [U-14C]deoxycytidine (462 mCi/mmol) were obtained from Amersham Corp (Arlington Heights, Ill.). All unlabeled ribonucleosides and deoxyribonucleosides, *Micrococcus lysodeikticus* DNA polymerase, calf thymus DNA, and Dowex 50 x 4 200-400 (Dow Chemical Co., Midland, Mich.) were purchased from Sigma Chemical Co. (St. Louis, Mo.). Affi-Gel 601 was obtained from Bio-Rad Laboratories (Richmond, Calif.). Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) was obtained from Burroughs-Wellcome Co., Research Triangle Park, N. C.

*Cell cultures.* The MolT-4 T-lymphoblast line was obtained from Hem Research, Inc., Rockville, Md., and was originally derived from a patient with acute lymphoblastic leukemia. Cultures were maintained in exponential growth in RPMI-1640 medium plus 10% horse serum.

*Deoxyribonucleoside pool measurements.* Cells were incubated at a concentration of 106/ml in RPMI plus 10% heat-inactivated horse serum at 37°C for 1 h with or without additives. Levels of dATP, dGTP, and dTTP were determined in 1-106 cells; dCTP levels were determined in 1-105 cells. At the end of the incubation period, cold RPMI medium (50 μl) was added. The cells were sedimented at 450 g for 5 min at 4°C and washed once with the same conditions in 1 ml 150 mM NaCl, 10 mM Tris, pH 7.4 (Buffer A). The intracellular deoxyribonucleotides were extracted from the cell pellet with 1 ml 60% methanol at -20°C for 12 h, the methanol evaporated, and the residue resuspended in 50 μl of distilled H2O for assay. Deoxyribonucleoside triphosphate recovery under these conditions was 83-95% (mean ± 1 SD; n = 5).

Deoxyribonucleoside triphosphate levels were determined with a modification of the DNA polymerase assay, as previously described (18). [3H]dTTP (3 Ci/mmol) was used for dATP, dGTP, and dTTP assays, and [3H]dCTP (3 Ci/mmol) for the dTTP assays. All assays were performed in duplicate with 0.3 U of DNA polymerase, 100 pmol of the nonlimiting deoxyribonucleotide, and 10 μl of cell extract in a final volume of 200 μl. Standard curves were linear from 2 to 10 pmol of limiting deoxyribonucleotide, and samples were diluted to fall within this range.

*Radioisotope incorporation into DNA and RNA.* After incubation of cells with labeled nucleosides, the RNA and DNA components of acid-precipitable cellular material were separated by methods similar to those described by Plagemann (25). Duplicate 1-ml aliquots of 1-106 cells were harvested, washed with 1 ml of Buffer A, and precipitated with 1 ml of cold 0.5 N perchloric acid (PCA). All precipitates throughout the procedure were collected by centrifugation at 900 g for 6 min. The PCA precipitates were washed with 1 ml of cold 10% TCA and then with 1 ml of cold ether:ethanol (1:1). The RNA was hydrolyzed in 0.4 ml of 0.3 N KOH over 18 h at 37°C. The hydrolysate was cooled to 4°C, cold 10 N PCA (10 μl) was
added, and the mixture was centrifuged as above. The resulting supernate, which contained hydrolyzed RNA, was removed, immediately neutralized with 200 μl of 0.7 N cold KOH, and recentrifuged to remove insoluble salts. Precipitated DNA from the KOH hydrolysis was washed twice with 2 ml of cold 10% TCA, resuspended in 0.6 ml of 10% TCA, and heated at 70°C for 45 min. The entire hydrolysate, which contained either DNA or RNA, was added to 10 ml of Aquasol (New England Nuclear) and counted in a Packard Tricarb scintillation counter (Packard Instrument Co., Inc., Downers Grove, Ill.). Differential 14C and 3H incorporation into DNA was measured by the method of Kobayashi and Maudsley (26) with a counting efficiency of 21% for 3H and 75% for 14C. The sum of the radioactivities recovered in the RNA and DNA hydrolysates was 96±7% (mean±1 SD; n = 5) of that recovered in the whole-cell TCA precipitate.

The distribution of [3H]uridine incorporation into either the 2',3'-UMP or the 2',3'-CMP products of RNA hydrolysis was determined by the method of Kat and Comb (27); 2',3'-UMP was separated from 2',3'-CMP by cation exchange. The Dowex 50 column, 1 × 5 cm (200–400 mesh, four timescross-linked), was washed with 20 ml of 3 N HCl, 20 ml of H2O, and 20 ml of 0.05 N HCl between samples. The flow rate was 0.5 ml/min, and 1-ml fractions were collected.

The RNA hydrolysate (0.6 ml of 0.3 N KOH) of cells labeled with [3H]uridine (obtained as described above) was acidified at 0°C with 10 N PCA (37 μl) and centrifuged at 900 g for 5 min at 4°C. The supernate was neutralized to pH 5–8 with 1 N KOH at 0°C, centrifuged, and 200 μl of the supernate was diluted with 200 μl of 0.1 N HCl before application on the column. The 2',3'-UMP component was collected by washing with 6 ml of 0.05 N HCl; the 2',3'-CMP component was eluted with 10 ml of 0.5 N NaOH. The 1-ml fractions were counted directly in 10 ml Aquasol. Recoveries of labeled UMP and CMP ranged from 90 to 100%.

Ribonucleotide and deoxyribonucleotide separations. An affinity gel (Affi-Gel 601) that selectively binds cis-diol compounds at high pH was used to separate deoxyribonucleotides from ribonucleotides (Fig. 1). The gel was suspended in 50 mM Hepes, pH 5.5, and 50 mM MgCl2 (Buffer B) and packed in a 1-cm diameter column at a total volume of 3 ml. Flow rate was 0.5 ml/min, and 1-ml fractions were collected.

Molt-4 cells labeled with [3H]cytidine were washed with 2 ml of Buffer A and extracted in 60% methanol as described above, the methanol was evaporated, and the residue was resuspended in 0.5 ml of Buffer B and applied to the column. Deoxyribonucleotides were collected by washing with 10 ml of Buffer B; the ribonucleotides were subsequently eluted from the column with 50 mM of sodium phosphate buffer, pH 6.0. Similar results were obtained when 100 mM of sodium acetate, pH 5.0, was used as the eluting buffer. The 1-ml fractions were counted directly in 10 ml of Aquasol. Recoveries of labeled ribo- and deoxyribonucleotides were consistently in the range of 95–100%.

RESULTS

Effects of deoxyadenosine and deoxyguanosine on deoxyribonucleotide pools, DNA synthesis, and RNA synthesis. Incubation of cells with 5 μM EHNA plus 50 μM deoxyadenosine inhibited the incorporation of [3H]thymidine, [3H]uridine, [3H]deoxyuridine, and [3H]cytidine into DNA (Table I). Control experiments showed little effect of 5 μM EHNA or of 50 μM deoxyadenosine alone on DNA synthesis. Deoxyguanosine alone (50 μM) also inhibited the incorporation of [3H]thymidine, [3H]deoxyuridine, and [3H]uridine into DNA.

As shown in Table II, incubation of Molt-4 lymphoblasts with increasing concentrations of deoxyadenosine from 0 to 50 μM in the presence of 5 μM EHNA for 1 h resulted in a fivefold increment in dATP levels and a concomitant depletion of the dCTP pool to undetectable levels. dTTP and dGTP pools remained relatively constant. [3H]Uridine was added to these cells for an additional 2.5-h incubation period. There was a reduction in the incorporation of this isotope into DNA with increasing concentrations of deoxyadenosine, but incorporation into RNA was not decreased.

Similar experiments were carried out with deoxyguanosine (0–50 μM) alone (Table III). As deoxyguanosine concentrations were increased from 5 to 25 μM, intracellular levels of dGTP rose more than fivefold and there was a substantial fall in the incorporation of [3H]uridine into DNA. There was no decline in the incorporation of [3H]uridine into RNA. dCTP levels fell as the concentration of deoxyguanosine was increased, whereas dTTP levels remained relatively
constant. dATP levels, on the other hand, increased progressively from 66 to 110 pmol/10⁶ cells.

The relative incorporation of [³H]uridine into either the cytosine or uracil residues of RNA was determined by analysis of the distribution of incorporation of [³H]-uridine into the 2',3'-UMP and 2',3'-CMP components of the RNA hydrolysate (Table IV). T lymphoblasts incubated with [³H]uridine for 75 and 150 min incorporated 75 and 66% of the total radioactivity into the 2',3'-UMP component of the hydrolysate. Preincubation with deoxyadenosine (50 µM) plus EHNA (5 µM) increased the total incorporation of [³H]uridine into RNA; most of the radioactivity was still in the 2',3'-UMP component of the RNA hydrolysate after either a 75- (86%) or a 150-min (77%) incubation with [³H]uridine. Similar results were obtained when cells were preincubated with deoxyguanosine (50 µM).

**Table I**

**Effects of Deoxyadenosine and Deoxyguanosine on Incorporation of Nucleotides into DNA**

<table>
<thead>
<tr>
<th>Additive</th>
<th>[³H]dThd (cpm)</th>
<th>[¹⁴C]dCyd (cpm)</th>
<th>[³H]Urd (cpm)</th>
<th>[³H]Urd (cpm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EHNA (5 µM)</td>
<td>102±6 (4)</td>
<td>97±4 (4)</td>
<td>102, 97 (2)</td>
<td>100, 99 (2)</td>
</tr>
<tr>
<td>Deoxyadenosine (50 µM)</td>
<td>94±10 (8)</td>
<td>75±2 (6)</td>
<td>114, 96 (2)</td>
<td>86±4 (2)</td>
</tr>
<tr>
<td>EHNA (5 µM) + deoxyadenosine (50 µM)</td>
<td>9±10 (8)</td>
<td>23±7 (4)</td>
<td>24, 21 (2)</td>
<td>6±1 (2)</td>
</tr>
<tr>
<td>Deoxyguanosine (50 µM)</td>
<td>25±1 (4)</td>
<td>— (2)</td>
<td>28, 27 (2)</td>
<td>10, 2, 6 (3)</td>
</tr>
</tbody>
</table>

Cells were incubated at a concentration of 1 x 10⁶/ml in RPMI plus 10% heat-inactivated horse serum for 1 h in the presence of the additive indicated. Labeled nucleosides were added for a further 75-min incubation period at concentrations of 0.1 µM. Nucleoside specific activities: [³H]dThd (9 Ci/mmol), [¹⁴C]dCyd (185 mCi/mmol), [³H]Urd (5.6 Ci/mmol), [³H]dUrd (4.4 Ci/mmol), and [³H]Urd (8.1 Ci/mmol). Values for four or more determinations represent the mean ± SD. Mean control counts for experiments: [³H]dThd (19,468 cpm), [¹⁴C]dCyd (7,310 cpm), [³H]Cyd (2,864 cpm), [³H]dUrd (13,597 cpm), and [³H]Urd (8,274 cpm).

**Table II**

**Effects of Increasing Deoxyadenosine Concentrations on Deoxyribonucleotide Pools, DNA Synthesis, and RNA Synthesis**

<table>
<thead>
<tr>
<th>Deoxyadenosine concentration</th>
<th>dATP (pmol/10⁶ cells)</th>
<th>dGTP (cpm)</th>
<th>dCTP (pmol/10⁶ cells)</th>
<th>dTTP (cpm)</th>
<th>[³H]Uridine into DNA (cpm)</th>
<th>[³H]Uridine into RNA (cpm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>µM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>66±5*</td>
<td>24±3*</td>
<td>2.5±0.3*</td>
<td>37±9‡</td>
<td>27,822</td>
<td>100</td>
</tr>
<tr>
<td>1</td>
<td>57</td>
<td>23</td>
<td>2.1</td>
<td>36</td>
<td>27,491</td>
<td>99</td>
</tr>
<tr>
<td>5</td>
<td>70</td>
<td>9</td>
<td>2.0</td>
<td>39</td>
<td>23,483</td>
<td>84</td>
</tr>
<tr>
<td>10</td>
<td>109</td>
<td>13</td>
<td>1.5</td>
<td>34</td>
<td>17,473</td>
<td>63</td>
</tr>
<tr>
<td>25</td>
<td>206</td>
<td>15</td>
<td>0.1</td>
<td>44</td>
<td>4,509</td>
<td>16</td>
</tr>
<tr>
<td>50</td>
<td>318</td>
<td>15</td>
<td>&lt;0.1</td>
<td>46</td>
<td>2,226</td>
<td>8</td>
</tr>
</tbody>
</table>

Cells were incubated at a concentration of 10% in RPMI plus 10% heat-inactivated horse serum for 1 h with 5 µM of EHNA and deoxyadenosine at the indicated concentrations. [³H]Uridine (40 nM, 20 Ci/mmol) was added for an additional 2.5 h, and incorporation into RNA and DNA was measured as detailed in Methods.

* Mean±SD in four experiments.
† Mean±SD in 12 experiments.
TABLE III

Effects of Increasing Deoxyguanosine Concentrations on Deoxyribonucleotide Pools, DNA Synthesis, and RNA Synthesis

<table>
<thead>
<tr>
<th>Deoxyadenosine concentration ((\mu M))</th>
<th>dATP</th>
<th>dGTP</th>
<th>dCTP</th>
<th>dTTP</th>
<th>([^3H])Uridine into DNA (cpm)</th>
<th>([^3H])Uridine into RNA (cpm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>66±5*</td>
<td>24±3*</td>
<td>2.5±0.3*</td>
<td>37±9†</td>
<td>20,601</td>
<td>74,269</td>
</tr>
<tr>
<td>1</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>20,921</td>
<td>88,241</td>
</tr>
<tr>
<td>5</td>
<td>79</td>
<td>31</td>
<td>1.3</td>
<td>44</td>
<td>15,201</td>
<td>89,494</td>
</tr>
<tr>
<td>10</td>
<td>91</td>
<td>79</td>
<td>1.2</td>
<td>39</td>
<td>4,663</td>
<td>22</td>
</tr>
<tr>
<td>25</td>
<td>102</td>
<td>174</td>
<td>1.1</td>
<td>40</td>
<td>1,568</td>
<td>8</td>
</tr>
<tr>
<td>50</td>
<td>110</td>
<td>305</td>
<td>0.3</td>
<td>31</td>
<td>443</td>
<td>2</td>
</tr>
</tbody>
</table>

Cells were incubated as detailed in Table I with increasing concentrations of deoxyguanosine rather than deoxyadenosine and EHNA.

* Mean±SD in four experiments.
† Mean±SD in 12 experiments.

Centrations from 100 \(\mu M\) to 5 mM progressively inhibited incorporation of both \([^3H]\)deoxyuridine and \([^{14}C]\)thymidine into DNA (Fig. 2A). Incorporation of \([^3H]\)uridine, however, had fallen to 20% of control values at 100 \(\mu M\) hydroxyurea, a concentration that left \([^{14}C]\)thymidine incorporation relatively unaffected (Fig. 2B). Deoxyguanosine alone exhibited effects similar qualitatively to those observed with hydroxyurea. Incorporation of \([^3H]\)uridine into DNA was markedly inhibited at a concentration of 10 \(\mu M\), whereas incorporation of thymidine and deoxyuridine into DNA was inhibited to a similar degree only at deoxyguanosine concentrations of 50 \(\mu M\) or above (Fig. 3). Similar results were obtained with deoxyguanosine in the presence of EHNA (data not shown). In contrast to these findings with hydroxyurea or deoxyguanosine, deoxyadenosine plus 5 \(\mu M\) EHNA inhibited the incorporation of labeled uridine into DNA to an extent similar to that observed with \([^{14}C]\)thymidine or \([^3H]\)deoxyuridine (Fig. 4). In addition, there was no differential inhibition of incorporation of \([^3H]\)cytidine as compared with \([^{14}C]\)deoxycytidine into DNA under these conditions (data not shown). To control for potential artifacts induced by the double-labeling technique, the simultaneous incorporations of \([^3H]\)thymidine and of \([^{14}C]\)thymidine were measured in the presence of increasing concentrations of hydroxyurea and were found to be identical (data not shown).

**Effects of hydroxyurea, deoxyguanosine, and deoxyadenosine plus EHNA on incorporation of \([^3H]\)cytidine into ribonucleotide pools.** Cells were preincubated for 1 h with deoxyribonucleoside (50 \(\mu M\)) or hydroxyurea (2.5 mM) at concentrations known to inhibit \([^3H]\)uridine incorporation into DNA by >90%. Intracellular ribo- or deoxyribonucleotides were extracted in 60% methanol and separated by affinity chromatography as described in Methods.

TABLE IV

[^3H]Uridine Incorporation into the UMP and CMP Components of RNA

<table>
<thead>
<tr>
<th>Additives</th>
<th>Time (min)</th>
<th>[^3H]Uridine into 2',3'-UMP (cpm)</th>
<th>% Total</th>
<th>[^3H]Uridine into 2',3'-CMP (cpm)</th>
<th>% Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>75</td>
<td>22,252</td>
<td>75</td>
<td>7,272</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>150</td>
<td>34,817</td>
<td>66</td>
<td>18,041</td>
<td>34</td>
</tr>
<tr>
<td>Deoxyadenosine (50 (\mu M))</td>
<td>75</td>
<td>27,339</td>
<td>86</td>
<td>4,363</td>
<td>14</td>
</tr>
<tr>
<td>+ EHNA (5 (\mu M))</td>
<td>150</td>
<td>50,712</td>
<td>77</td>
<td>14,816</td>
<td>23</td>
</tr>
<tr>
<td>Deoxyguanosine (50 (\mu M))</td>
<td>75</td>
<td>31,425</td>
<td>84</td>
<td>5,987</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>150</td>
<td>52,539</td>
<td>77</td>
<td>15,269</td>
<td>23</td>
</tr>
</tbody>
</table>

Cells were incubated at a concentration of 1 \(\times 10^6/ml\) in RPMI plus 10% heat-inactivated horse serum for 1 h in the presence of the additive indicated. \([^3H]\)Uridine (40 nM, 20 Ci/mmol) was added to 3-ml cultures for either 75 or 150 min. The incorporation of \([^3H]\)uridine into the 2',3'-UMP and the 2',3'-CMP components of the RNA hydrolysate was determined as described in Methods.
FIGURE 2. Differential incorporation of nucleosides into DNA: effects of increasing concentrations of hydroxyurea. Cells were incubated at a concentration of 1 x 10^6/ml in RPMI plus 10% heat-inactivated horse serum in the presence of the hydroxyurea concentration indicated for 1 h. Labeled nucleosides were added for an additional 2.5-h incubation period. (A) •—•, [3H]thymidine (50 nM, 515 Ci/mmol); O—O, [3H]deoxyuridine (50 nM, 9 Ci/mmol). (B) •—•, [3H]thymidine, as in Panel A; O---O, [3H]uridine (40 nM, 24.2 Ci/mmol). Values are expressed as a percentage of control values obtained in the absence of additives, and are the mean of duplicate determinations of a single experiment. Similar results were obtained in two additional experiments. The mean control cpm ± 1 SD for 12 determinations: (A) [3H]thymidine 7,442 ± 321, [3H]deoxyuridine 9,072 ± 389; (B) [3H]thymidine 7,442 ± 492, [3H]uridine 11,284 ± 551.

After incubation with hydroxyurea, there was a decrease in the incorporation of [3H]cytidine into deoxyribonucleotides to a mean of 31% of control values and a corresponding increase to 144% of control in the labeled ribonucleotide pool (Table V); almost identical results were obtained with deoxyguanosine. Incubation with deoxyadenosine plus EHNA, however, yielded intermediate results with a less pronounced fall in counts in the deoxyribonucleotide fraction (70% of control) and a more modest increment in the ribonucleotide component (110% of control).

DISCUSSION

Deoxyribonucleoside toxicity for lymphoid cells is currently felt to account, at least in part, for the immunodeficiency syndromes associated with ADA and PNP deficiency. We have previously demonstrated marked cytotoxicity of deoxyadenosine plus EHNA and of deoxyguanosine alone for human T lymphoblasts, an effect which is significantly greater than the toxicity of these compounds for cultured human B lymphoblasts. In this study, we have focused on the mechanism of toxicity of deoxyribonucleosides in human T lympho-

FIGURE 4. Differential incorporation of nucleosides into DNA: effects of increasing concentrations of deoxyadenosine. Experimental conditions and symbols are identical to those in Fig. 2.

blasts because it is this effect that appears to be of major clinical importance.

We have examined the effects of deoxyribonucleo-
sides on the simultaneous incorporation of [3H]uridine into RNA and into DNA in cultured T cells. Because the incorporation of any nucleoside is a function not only of nucleic acid synthesis, but also of nucleoside transport, phosphorylation, and dilution in an unlabeled nucleotide pool, incorporation studies in the presence of exogenous deoxyribonucleosides that may interfere with these processes must be stringently

FIGURE 3. Differential incorporation of nucleosides into DNA: effects of increasing concentrations of deoxyguanosine. Experimental conditions and symbols are identical to those in Fig. 2.
controlled. Comparison of the incorporation of $[^3H]$uridine into DNA and RNA allows us to control for interference with both the transport and the phosphorylation of this labeled nucleoside. Our results support a progressive inhibition of DNA synthesis, but not of RNA synthesis, by increasing concentrations of deoxyadenosine plus EHNA and deoxyguanosine. Our studies confirm and expand those reported by others in which the toxic effect of deoxyadenosine plus EHNA on mouse leukemia cells was evaluated with microfluorometry, as well as the incorporation of $[^3H]$thymidine into DNA and $[^3H]$uridine into RNA (15).

One hypothesis to account for deoxyribonucleoside-mediated inhibition of DNA synthesis is an inhibition of the enzyme ribonucleotide reductase by elevated levels of dATP or dGTP. This enzyme catalyzes the reduction of ribonucleoside diphosphates to their corresponding 2'-deoxy derivatives and insures an adequate supply of deoxyribonucleotides for DNA synthesis. In partially purified cell extracts of Novikoff rat tumor cells, dATP has been demonstrated to inhibit all reductions catalyzed by this enzyme, whereas dGTP inhibits the reduction of CDP, GDP, and UDP, but may stimulate the reduction of ADP (22). In our study, we have documented a progressive increase in dATP or dGTP levels in T lymphoblasts and a decline in the much smaller dCTP pool in the presence of an increasing concentration of deoxyadenosine or deoxyguanosine, respectively. These results confirm those reported for other cell systems at isolated high concentrations of deoxyribonucleosides (15, 16, 19, 20). In contrast to other studies, however, we have observed no definite effect of either deoxyribonucleoside tested on dTTP pools and, in the presence of deoxyguanosine, we have noted a twofold increase in the dATP pool, an effect consistent with the putative activation of ribonucleotide reductase by dGTP.

The depletion of dCTP and the reversal of toxicity with deoxycytidine, i.e., deoxycytidine rescue, have frequently been cited as the major evidence for ribonucleotide reductase inhibition in deoxyribonucleoside toxicity (16, 17, 20). Such an interpretation may be erroneous, because the reversal or prevention of deoxyribonucleoside-mediated toxicity by deoxycytidine could be attributed to a number of mechanisms other than bypass of the block created by inhibition of ribonucleotide reductase. For example, the effect of deoxycytidine could be a result of inhibition of deoxyadenosine or deoxyguanosine phosphorylation. There is good evidence for the identity of deoxycytidine kinase and deoxyguanosine kinase in mouse T lymphoma cells (20), and deoxycytidine could completely prevent toxicity by competitive inhibition of deoxyguanosine phosphorylation. Whereas deoxy-

### TABLE V

$[^3H]$Cytidine Incorporation into Ribonucleotide and Deoxyribonucleotide Pools in T Lymphoblasts

<table>
<thead>
<tr>
<th>Additives</th>
<th>Experiment (n)</th>
<th>Deoxyribonucleotides</th>
<th>Ribonucleotides</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% control</td>
<td>% control</td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>1 (3)</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>2 (2)</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td></td>
<td>3 (3)</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Hydroxyurea (2.5 mM)</td>
<td>1 (2)</td>
<td>25</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>2 (1)</td>
<td>26</td>
<td>142</td>
</tr>
<tr>
<td></td>
<td>3 (2)</td>
<td>42</td>
<td>139</td>
</tr>
<tr>
<td>Deoxyguanosine (50 μM)</td>
<td>1</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>2 (1)</td>
<td>33</td>
<td>152</td>
</tr>
<tr>
<td></td>
<td>3 (2)</td>
<td>41</td>
<td>137</td>
</tr>
<tr>
<td>Deoxyadenosine (50 μM) + EHNA (5 μM)</td>
<td>1 (2)</td>
<td>60</td>
<td>109</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>3 (2)</td>
<td>79</td>
<td>110</td>
</tr>
</tbody>
</table>

Molt-4 lymphoblasts (10^6 cells/ml) were incubated in 2.5 ml of RPMI plus 10% heat-inactivated horse serum for 1 h at 37°C in the presence of the additives indicated. $[^3H]$Cytidine (28 Ci/mmol; 50 nM in experiments 1 and 2, 0.12 μM in experiment 3) was added for a further 75-min incubation period. n = number of determinations per experiment. Control values: experiment 1, deoxyribonucleotides 3,175 cpm, ribonucleotides 46,419 cpm; experiment 2, deoxyribonucleotides, 2,761 cpm, ribonucleotides 88,005 cpm; experiment 3, deoxyribonucleotides 9,753 cpm, ribonucleotides 212,050 cpm.
Adenosine kinase activity appears to reside in two separate enzymes in this system (16) and may not be totally inhibited by deoxycytidine, dCTP can inhibit deoxyadenosine phosphorylation in cell extracts (28); thus, an increase in the intracellular dCTP pool after the addition of deoxycytidine could prevent an accumulation of dATP.

Because deoxycytidine rescue could be a result of a number of different mechanisms and thus is poor evidence for ribonucleotide reductase inhibition and because dCTP depletion could also result from several of the alternatives suggested, we have tested more directly the hypothesis that deoxyribonucleoside toxicity is mediated by an inhibition of this enzyme. In addition, we have compared the effects of deoxyguanosine with the effects of hydroxyurea, a known inhibitor of ribonucleotide reductase (29–31), on the incorporation of ribonucleosides and deoxyribonucleosides into DNA.

Ribonucleotide reductase activity is required for the incorporation of uridine, but not deoxyuridine or thymidine, into DNA (Fig. 5). Inhibition of this enzyme would thus be expected to result in a greater decrease in the incorporation of uridine than of either deoxyuridine or thymidine into DNA. Just such a differential effect was observed with hydroxyurea at concentrations in the millimolar range and with deoxyguanosine at concentrations in the micromolar range. Although these data are consistent with an inhibition of ribonucleotide reductase, one must consider other possibilities. Very little [3H]uridine is incorporated into the cytosine residues of RNA (Table IV), which suggests that only a small fraction of [3H]UTP is converted via CTP synthetase (reaction 4, Fig. 5) into the cytidine nucleotide pools. Thus, it is highly unlikely that a significant amount of [3H]uridine is incorporated into DNA via dCTP under the conditions of our double-label experiments. Assuming that the majority of [3H]uridine is incorporated into DNA via dTTP, one may conclude that the site of the differential inhibition of [3H]uridine incorporation as compared with [14C]thymidine incorporation into DNA must occur between transport of uridine and the phosphorylation of dTTP (Fig. 5).

Because uridine incorporation into RNA is not inhibited, uridine phosphorylation and transport, and UMP phosphorylation are unimpaired. We have excluded involvement of thymidylate synthetase (reaction 7, Fig. 5) by demonstrating no difference in the inhibition of incorporation of deoxyuridine as compared with thymidine into DNA in cells incubated with either deoxyguanosine or hydroxyurea. Our data might also be explained by a relative stimulation of thymidine and deoxyuridine incorporation into DNA as a result of decreased feedback inhibition of thymidine kinase (reaction 8, Fig. 5) by depleted dTTP pools (32). However, we have found that dTTP pools remain relatively constant with increasing dGTP levels.

After careful consideration of these alternative explanations, we conclude that our results are due to inhibition of either the reduction of UDP by ribonucleotide reductase or of the reversible conversion of dUDP to dUMP catalyzed by thymidylate kinase. Because thymidylate kinase does not appear to be regulated allosterically by nucleotides (33), it is most probable that our results are explained by an inhibition of ribonucleotide reductase.

Further support for this conclusion can be derived from our studies on the incorporation of [3H]cytidine into ribonucleotide and deoxyribonucleotide pools. [3H]Cytidine must be phosphorylated to CDP and reduced by ribonucleotide reductase to enter the deoxyribonucleotide pool (Fig. 5). A block of ribonucleotide reductase should substantially increase counts appearing in the ribonucleotide fractions while decreasing counts in the deoxyribonucleotide pool. This result was obtained with both hydroxyurea and deoxyguanosine.

Deoxyadenosine plus EHNA, in contrast to either hydroxyurea or deoxyguanosine, produced little, if any, differential effect on the incorporation of uridine and thymidine into DNA. In addition, there was a far more modest increment in the ribonucleotide pool at a concentration of deoxyadenosine which effectively inhibited DNA synthesis.
Interpretation of these results requires careful consideration of possible changes in the dTTP pool. An increasing pool of dTTP could inhibit the incorporation of thymidine and deoxyuridine into DNA as a result of greater feedback inhibition of thymidine kinase and/or dilution of the labeled dTTP formed. This seems unlikely because we found no significant elevation of the dTTP pool after a 1-h incubation with 50 μM deoxyadenosine plus 5 μM EHNA. In addition, we controlled for possible changes in pool size by comparing both [3H]uridine and [3H]deoxyuridine incorporation with [14C]thymidine incorporation into DNA.

Because [3H]uridine can be incorporated into DNA through both the dTTP and dCTP pools (Fig. 5), it is also conceivable that deoxyadenosine and deoxyguanosine could have different effects on the relative distribution of [3H]uridine into these nucleotide pools. This might, in turn, account for variable dilution of the tritium label in pools of different sizes and an alteration in the incorporation of tritium into DNA. We have found that the incorporation of [3H]uridine into the cytidine nucleotide pool in the presence of deoxyadenosine is small, and is identical to that obtained with deoxyguanosine. These experiments demonstrate that the major route of [3H]uridine incorporation into DNA is through the dTTP pool, which remains constant in size in the presence of both deoxyadenosine and deoxyguanosine. In view of these controls, our data suggest that deoxyadenosine, in the presence of an inhibitor of adenosine deaminase, may inhibit DNA synthesis by mechanisms other than, or in addition to, inhibition of ribonucleotide reductase. One recently espoused possibility is that an increased concentration of deoxyadenosine leads to an accumulation of S-adenosylhomocysteine by suicide inactivation of S-adenosylhomocysteine hydrolase, thereby depleting the cell of S-adenosylmethionine and preventing essential methylation reactions (34).

The apparent difference in the mechanisms of toxicity of deoxyguanosine and deoxyadenosine could account for the clinical differences in the syndromes associated with PNP deficiency (isolated T-cell dysfunction) and ADA deficiency (combined T- and B-cell dysfunction).

ACKNOWLEDGMENTS

We wish to thank Ms. Elizabeth Ashcraft and Mr. Jonathan Klein for expert technical assistance.

This work was supported by the National Institutes of Health grants 5 R01-AM19045 and 3 P60 AM20557, and National Foundation—March of Dimes grant 1-393.

REFERENCES


